SEC Filing Summary: Prana Biotechnology Limited
Business Context and Reporting Period
This Form 6-K was filed by Prana Biotechnology Limited (ACN: 080 699 065), a foreign private issuer, on August 4, 2009. The filing covers the month of August 2009 and serves to disclose changes in directors' relevant interests in securities pursuant to ASX Listing Rule 3.19A.2. The registrant files annual reports under Form 20-F.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The document is strictly a regulatory disclosure regarding changes in director shareholdings and option holdings.
Material Changes Versus Prior Period
The primary material change reported is the reduction in option holdings for four directors due to the expiry of PBTAC Options on July 31, 2009. No new securities were acquired or disposed of via trade during this period.
- Brian Meltzer: Options reduced from 950,000 to 650,000. Direct shares remained at 0; indirect shares remained at 326,666.
- Geoffrey Kempler: Options reduced from 3,000,000 to 2,000,000. Direct shares remained at 30,000; indirect shares remained at 17,025,000.
- George Mihaly: Options reduced from 950,000 to 650,000. Direct shares remained at 166,666; indirect shares remained at 60,000.
- Peter Marks: Options reduced from 950,000 to 650,000. Direct shares remained at 0; indirect shares remained at 43,111.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The only noted event is the administrative adjustment of option totals due to expiry.
Investor Verification Checklist
- Verify the total number of outstanding options for the company following the July 31, 2009 expiry.
- Confirm the current shareholding percentages of the directors relative to the total issued capital.
- Review the terms of the "PBTAC Options" to understand the vesting schedule and expiry conditions.
- Check for any subsequent filings regarding the "The CFO Solution" contract mentioned in Part 2 of the notices, as no specific details were provided in this text.